BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1482 related articles for article (PubMed ID: 26386489)

  • 1. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring.
    Mannucci PM; Cugno M
    Thromb Res; 2015 Nov; 136(5):851-4. PubMed ID: 26386489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
    Polito MG; Kirsztajn GM
    J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic microangiopathies.
    Rosove MH
    Semin Arthritis Rheum; 2014 Jun; 43(6):797-805. PubMed ID: 24360024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification.
    Shenkman B; Einav Y
    Autoimmun Rev; 2014; 13(4-5):584-6. PubMed ID: 24418304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab.
    Pecoraro C; Ferretti AV; Rurali E; Galbusera M; Noris M; Remuzzi G
    Am J Kidney Dis; 2015 Dec; 66(6):1067-70. PubMed ID: 26409664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).
    Licht C; Stapenhorst L; Simon T; Budde U; Schneppenheim R; Hoppe B
    Kidney Int; 2004 Sep; 66(3):955-8. PubMed ID: 15327386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?
    Shibagaki Y; Fujita T
    Hypertens Res; 2005 Jan; 28(1):89-95. PubMed ID: 15969259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HUS and TTP: traversing the disease and the age spectrum.
    Donadelli R; Sinha A; Bagga A; Noris M; Remuzzi G
    Semin Nephrol; 2023 Jul; 43(4):151436. PubMed ID: 37949684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
    Noris M; Mescia F; Remuzzi G
    Nat Rev Nephrol; 2012 Nov; 8(11):622-33. PubMed ID: 22986360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.
    Laurence J; Haller H; Mannucci PM; Nangaku M; Praga M; Rodriguez de Cordoba S
    Clin Adv Hematol Oncol; 2016 Nov; 14 Suppl 11(11):2-15. PubMed ID: 27930620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs).
    Williams LA; Marques MB;
    Am J Clin Pathol; 2016 Feb; 145(2):158-65. PubMed ID: 27124904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome.
    Tsai HM
    Transfus Med Rev; 2014 Oct; 28(4):187-97. PubMed ID: 25280590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic approach to microangiopathic hemolytic disorders.
    Kottke-Marchant K
    Int J Lab Hematol; 2017 May; 39 Suppl 1():69-75. PubMed ID: 28447417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The frontline of TMA management].
    Saito K; Matsumoto M
    Rinsho Ketsueki; 2022; 63(5):463-470. PubMed ID: 35662172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical reduction of plasma ADAMTS13 activity by a non-IgG-type inhibitor in a patient with hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli.
    Nakayama S; Hirashio S; Yorishima H; Doi T; Yoshida Y; Matsumoto M; Masaki T
    CEN Case Rep; 2019 Nov; 8(4):266-270. PubMed ID: 31177384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
    Wada H; Matsumoto T; Yamashita Y
    Semin Thromb Hemost; 2014 Nov; 40(8):866-73. PubMed ID: 25377323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of complement mediated thrombotic microangiopathies.
    Cataland SR; Wu HM
    Blood Rev; 2014 Mar; 28(2):67-74. PubMed ID: 24534133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
    Furlan M; Lämmle B
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura.
    Noris M; Remuzzi G
    Semin Nephrol; 2010 Jul; 30(4):395-408. PubMed ID: 20807612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.